We thought to evaluate progression-free survival of stage II A/B seminoma patients (pts) undergoing primary retroperitoneal lymph node dissection (RPLND) without adjuvant treatment. Aim is to present interim data of a feasibility study and a phase II trial.
INTRODUCTION AND OBJECTIVES:
We thought to evaluate progression-free survival of stage II A/B seminoma patients (pts) undergoing primary retroperitoneal lymph node dissection (RPLND) without adjuvant treatment. Aim is to present interim data of a feasibility study and a phase II trial.
METHODS: Prior to the phase II study, 9 patients have been treated within a pilot feasibility study. After IRB approval, additional 16 patients from 3/2016 to 9/2018 within the prospective phase II trial (NCT 2015053664) were accrued. All patients received primary retroperitoneal lymph node dissection (open or daVinci assisted) for stage IIA/B seminoma without adjuvant treatment. The data was analyzed for periand postoperative outcome including recurrence free survival. The trial will have to accrue 30 pts and was designed to exclude a > 30% recurrence to standard treatment.
RESULTS: Since 5.2014 twenty-five patients with seminomateous germ cell tumor have been included in both studies, including one patient with an atypical inguinal recurrence and one patient with a 6 cm marker negative recurrence (clinical stage IIC). Primary RPLND was performed in 5 patients with initial CSIIA. 16 and 4 patients experienced a recurrence under surveillance and after carboplatin adjuvant treatment, respectively. Mean tumor size was 3.0 cm with a mean OR time of 134 min and a mean blood loss of 74 cc. One patient after DaVinci RPLND developed a ureteral stricture requiring ileal ureter substitute. The mean follow-up is 24 month (range 3-54 months), 20/25 patients (80%) are free of recurrence. 5/ 25 (20%) developed a recurrence (4x outside field and 1x inside field) with a mean time to recurrence of 4.5 months. All patients received salvage treatment (4x CTX and 1x radiotherapy) and are currently recurrence free.
CONCLUSIONS: Primary RPLND in stage IIA/B seminoma patients is an experimental treatment approach in order to reduce long term toxicity and secondary malignancies. Interim results of this strategy justifies continuation of the study. This kind of surgery should only be performed within clinical trials in high volume referral centers.
Source of Funding: None

PD56-06
INTRODUCTION AND OBJECTIVES: Late relapse (>2 years) germ cell tumor (GCT) is associated with an increased rate of secondary somatic malignancy (SSM). We report our experience with SSM in the setting of late relapse and determine predictors of overall survival (OS).
METHODS: From 1985 to 2018, 46 patients with GCT and SSM at late relapse were identified. Clinical and pathologic parameters were reviewed. The Kaplan-Meier method was used to estimate OS from time of late relapse and a Cox proportional hazards model to assess predictors of OS.
RESULTS: Of 46 men (44 testicular primary, 2 mediastinal primary), median time to late relapse with SSM was 10.4 years (range, 2.3 to 38.1 years). Most (n[27, 59%) were symptomatic at presentation but 11 were detected by elevated tumor markers (AFP 8, HCG 2, both 1) and 8 by surveillance imaging. SSMs were predominately adenocarcinoma (25), sarcoma (14), poorly differentiated neoplasm (3), Wilms tumor (2), primitive neuroectodermal tumor (PNET) (1) and glioma (1). Median time to relapse was longer for adenocarcinoma vs other histotypes of SSM (14.6 vs 4.1 years, p < 0.001). The initial site of relapse was the retroperitoneum (RP, 26), pelvis (7), lung (6), retrocrural space (3), mediastinum (2), neck (1) and duodenum (1). Only 10 of 26 men with late relapse in the RP had undergone prior retroperitoneal lymph node dissection (RPLND) (all at outside institutions; variable templates) with histology in 7/10 showing teratoma. The other 16 men had received chemotherapy only (8), orchiectomy only for stage I (3), RPLND aborted due to cardiac arrest (1), and unknown (4). All 46 late relapses were managed with surgical resection; 26 also received chemotherapy (16 SSM-directed, 10 GCT-directed). Overall, 12 patients died and the median OS was 14.2 years. On univariable analysis, symptomatic presentation (HR [ 3.1), SSM at multiple sites (HR [ 3.9), extra-RP disease (HR: 3.9), and incomplete/no resection of SSM (HR [ 3.6) predicted mortality. On multivariable analysis, only extra-RP disease (HR [ 4.8) was independently associated with inferior OS (5-year OS, 82% v 52%, p [ 0.017).
CONCLUSIONS: SSM is an important potential complication of late relapse GCT and seems to be associated with the lack of resection of retroperitoneal metastases. Early identification and complete surgical resection prior to SSM arising in extra-RP sites is critical to optimizing outcomes.
Source of Funding:
This research was supported by the Sidney Kimmel Center for Prostate and Urologic Cancers and funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748.
PD56-07 OUTCOMES OF PENILE CANCER PATIENTS WITH MICRO-METASTASES IN DYNAMIC SENTINEL LYMPH NODE BIOPSY SPECIMENS. AN EUROGEN COLLABORATION.
Rachel A Khaw*, Manchester, United Kingdom; Joren Van Thoor, Maarten Albersen, Leuven, Belgium; Pedro Oliveira, Tony Elliott, Vijay Sangar, Maurice Lau, Arie Parnham, Manchester, United Kingdom INTRODUCTION AND OBJECTIVES: Prognosis of penile squamous cell carcinoma is determined by TNM staging. Inguinal nodal involvement can be associated with poor survival; therefore investigation of both clinically palpable and non-palpable nodes is imperative. Current management of positive nodes found through sentinel lymph node biopsy (SLNB) involves completion inguinal lymph node dissection (ILND). The need for completion ILND in patients with SLNB micro-metastasis is debatable. This retrospective two-centre eUROGEN cohort study investigates outcomes in patients with SLNB micro metastasis who go on to completion ILND.
METHODS: All patients with clinically non-palpable inguinal nodes underwent SLNB. Sentinel nodes were examined histologically, and the maximum diameter of any metastasis recorded. Any sentinel node containing a metastasis measuring 2mm was classified as having a micro-metastasis as defined by the TNM 8th ed. All tumour positive sentinel node cases underwent completion ILND. Tumour characteristics including staging and grading were recorded, in addition to histopathological findings of the ILND, local recurrence rates and follow-up.
RESULTS: A total of 421 inguinal regions in 240 patients with varying stages of disease (T1-3, G1-2) were included. Mean age was 64 (33-90) years. The median number of lymph nodes excised from each inguinal region at the time of SLNB was 2 (range 1-8). There were 50 cases which were tumour-positive (11.9%). Of these 50 cases, micro-metastases were found in 9 cases (18%), mean diameter 1.00mm (0.2-2.0mm). Completion ILND was performed in 7 of these cases (78%). No further positive nodes were noted in the completion ILND specimen. There were 0 local recurrences with a Vol. 201, No. 4S, Supplement, Sunday, May 5, 2019 THE JOURNAL OF UROLOGY Ò e1019
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